Bio

Arash has a background in molecular biology and chemistry, and earned his PhD in AI-driven drug discovery, where his work led to the identification of three candidate drugs for breast cancer, validated both in vitro and in vivo. Following this, he joined a lab at UCSF for his first postdoctoral position which led to a patent for AI drug discovery applications which led to multiple patents and articles. Throughout his career, Arash has also been involved in multiple ventures. He served as the Chief Scientific Officer at Nucleus Genomics with $17 million seed funding, and co-founded Lumos Bio, a stealth focused on RNA-targeted drug discovery. Currently, Arash is a NIH T32 fellow postdoc in the Ashley Lab and an investment fellow in Mubadala Capital

Stanford Advisors

Patents

  • Arash Keshavarzi. "United States Patent US12040094B2 Artificial intelligence-based methods for early drug discovery and related training methods", USPTO, Jul 16, 2024
  • Arash Keshavarzi Arshadi. "United States Patent WO/2023/154588 DEEP-LEARNING BASED METHODS FOR VIRTUAL SCREENING OF MOLECULES FOR MICRO RIBONUCLEIC ACID (MIRNA) DRUG DISCOVERY", WIPO, Aug 17, 2023

Contact

  • Academic
    arashk@stanford.edu
    University - Scholar Department: School of Medicine Position: Postdoctoral Scholar

Additional Info

  • Mail Code: 5151

Links